11.26
Schlusskurs vom Vortag:
$11.18
Offen:
$11.48
24-Stunden-Volumen:
62,959
Relative Volume:
0.59
Marktkapitalisierung:
$295.58M
Einnahmen:
$59,000
Nettoeinkommen (Verlust:
$-21.81M
KGV:
-1.0281
EPS:
-10.9518
Netto-Cashflow:
$-18.07M
1W Leistung:
-9.49%
1M Leistung:
-22.93%
6M Leistung:
+5.33%
1J Leistung:
+25.67%
Benitec Biopharma Inc Stock (BNTC) Company Profile
Firmenname
Benitec Biopharma Inc
Sektor
Branche
Telefon
(510) 780-0819
Adresse
3940 TRUST WAY, HAYWARD, CA
Vergleichen Sie BNTC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BNTC
Benitec Biopharma Inc
|
11.26 | 326.56M | 59,000 | -21.81M | -18.07M | -10.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-07 | Eingeleitet | TD Cowen | Buy |
2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
2024-09-12 | Eingeleitet | Guggenheim | Buy |
2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
2024-06-13 | Eingeleitet | Piper Sandler | Overweight |
2020-10-05 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2020-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
2016-02-26 | Herabstufung | Maxim Group | Buy → Hold |
2015-12-31 | Bestätigt | Maxim Group | Buy |
2015-09-16 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Benitec Biopharma Inc Aktie (BNTC) Neueste Nachrichten
What drives Benitec Biopharma Inc. stock priceRapidly growing investment returns - jammulinksnews.com
Benitec Biopharma Inc. Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com
What analysts say about Benitec Biopharma Inc. stockOutstanding growth strategies - jammulinksnews.com
Why Benitec Biopharma Inc. stock attracts strong analyst attentionSteady Income Ideas - Newser
Is Benitec Biopharma Inc. a good long term investmentConsistently exceptional gains - jammulinksnews.com
(BNTC) Investment Report - news.stocktradersdaily.com
Does Benitec Biopharma Inc. stock pay reliable dividendsFree Investment Community - Newser
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of “Buy” by Analysts - Defense World
What analysts say about Benitec Biopharma Inc. stock outlookSmart High Yield Swing Trades - Newser
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trial progress - Investing.com Australia
How Benitec Biopharma Inc. stock performs during market volatilityFree Stock Market Entry & Exit Signals - Newser
What makes Benitec Biopharma Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
Citizens JMP Reaffirms Their Buy Rating on Benitec Biopharma (BNTC) - The Globe and Mail
Benitec BioPharma stock maintains Market Outperform rating at JMP By Investing.com - Investing.com Canada
Benitec completes first cohort in gene therapy trial, advances to next phase By Investing.com - Investing.com South Africa
When the Price of (BNTC) Talks, People Listen - news.stocktradersdaily.com
Benitec Biopharma Advances BB-301 Clinical Study - TipRanks
Benitec Biopharma Provides Operational Updates - GlobeNewswire
Benitec Biopharma Inc. Provides Operational Updates - MarketScreener
Benitec Biopharma (BNTC) Moves Forward with Clinical Study Enrollment | BNTC Stock News - GuruFocus
Benitec completes first cohort in gene therapy trial, advances to next phase - Investing.com
Benitec's BB-301 Gene Therapy Achieves Key Safety Milestone, Phase 1b/2a Trial Set to Expand - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at TD Cowen - Defense World
Finanzdaten der Benitec Biopharma Inc-Aktie (BNTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Benitec Biopharma Inc-Aktie (BNTC) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):